US · BMY
Bristol-Myers Squibb Company
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Princeton, NY 10016
- Website
- bms.com
Price · as of 2025-12-31
$58.22
Market cap 127.01B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $66.72 | +14.6% |
| Intrinsic Value(DCF) | $31.14 | -46.51% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $27.44 | -52.88% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $20.70 | $48.21 | $19.26 | $0.00 | $36.52 |
| 2012 | $24.49 | $37.92 | $6.79 | $0.00 | $0.00 |
| 2013 | $37.69 | $42.51 | $4.57 | $0.00 | $2.24 |
| 2014 | $46.41 | $46.75 | $6.26 | $0.00 | $6.36 |
| 2015 | $46.14 | $46.35 | $7.17 | $0.00 | $11.40 |
| 2016 | $42.46 | $53.02 | $21.13 | $0.00 | $66.08 |
| 2017 | $50.79 | $55.97 | $29.20 | $0.00 | $9.08 |
| 2018 | $39.52 | $56.70 | $51.82 | $0.00 | $49.28 |
| 2019 | $47.93 | $51.27 | $37.02 | $3.59 | $46.88 |
| 2020 | $49.73 | $48.23 | $805.44 | $0.00 | $0.00 |
| 2021 | $58.31 | $61.75 | $743.30 | $0.00 | $52.71 |
| 2022 | $57.31 | $58.28 | $266.46 | $0.00 | $23.01 |
| 2023 | $48.77 | $56.60 | $7.48 | $0.00 | $22.63 |
| 2024 | $58.15 | $51.14 | $6.42 | $0.00 | $0.00 |
| 2025 | $62.34 | $66.72 | $9.48 | $0.00 | $27.43 |
AI valuation
Our deep-learning model estimates Bristol-Myers Squibb Company's (BMY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $66.72
- Current price
- $58.22
- AI upside
- +14.6%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$31.14
-46.51% upside
Graham-Dodd
—
— upside
Graham Formula
$27.44
-52.88% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BMY | Bristol-Myers Squibb Comp… | $58.22 | 127.01B | +15% | -47% | — | -53% | 18.03 | 6.89 | 2.64 | 11.25 | — | -5.68 | 67.65% | 26.34% | 14.63% | 40.54% | 17.21% | 7.73% | 2.55 | 8.41 | 1.26 | 1.08 | 2.54 | -17823.00% | -22.00% | -787.00% | 10.10% | 0.60 | 23.02% | 3.97% | 71.50% | 7.05% | 12.89 | 12.74 | 3.40 | 2.41 |
| CI | Cigna Corporation | $289.82 | 77.42B | -21% | +327% | -97% | +46% | 12.30 | 1.85 | 0.28 | 8.71 | 14.84 | -2.43 | 9.45% | 3.32% | 2.17% | 15.20% | 11.53% | 4.01% | 0.75 | 6.61 | 0.85 | 0.65 | 2.05 | 8292.00% | 1126.00% | -634.00% | 10.85% | 0.17 | 12.88% | 2.08% | 25.60% | 7.58% | 11.08 | 12.06 | 0.37 | 2.69 |
| CVS | CVS Health Corporation | $79.90 | 101.65B | -34% | -49% | — | -73% | 58.52 | 1.38 | 0.26 | 18.90 | — | -2.89 | 13.77% | 2.58% | 0.44% | 2.35% | 5.50% | 0.69% | 1.24 | 3.33 | 0.84 | 0.57 | 8.63 | -6202.00% | 785.00% | 2341.00% | 7.55% | 0.12 | 5.11% | 3.28% | 192.10% | 3.28% | 17.95 | 23.88 | 0.46 | 2.27 |
| ELV | Elevance Health Inc. | $320.00 | 70.63B | -31% | -45% | -71% | +61% | 11.52 | 1.49 | 0.33 | 9.21 | — | 15.04 | 25.56% | 4.07% | 2.84% | 13.29% | 10.26% | 4.75% | 0.76 | 5.79 | 1.24 | 1.24 | 2.46 | -218.00% | 1262.00% | -3027.00% | 4.87% | 0.21 | 4.76% | 2.34% | 27.00% | 7.36% | 10.97 | 28.03 | 0.45 | 2.82 |
| GSK | GSK plc | $59.13 | 119.27B | 0% | -48% | — | -38% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| HCA | HCA Healthcare, Inc. | $529.70 | 118.45B | -26% | -56% | -86% | -18% | 18.12 | -20.40 | 1.63 | 11.03 | 62.49 | -7.53 | 41.50% | 15.83% | 8.97% | -159.14% | 22.59% | 11.28% | -8.33 | 5.32 | 0.83 | 0.73 | 3.15 | 2900.00% | 708.00% | 3641.00% | 6.26% | 0.77 | 18.35% | 0.55% | 10.00% | 8.74% | 14.38 | 22.37 | 2.28 | 2.87 |
| MCK | McKesson Corporation | $987.37 | 121.87B | -46% | +187% | — | -38% | 26.01 | -43.65 | 0.25 | 17.57 | 174.88 | -6.68 | 3.48% | 1.22% | 0.92% | -172.11% | 1514.70% | 4.88% | -3.56 | 17.08 | 0.90 | 0.51 | 0.32 | 1487.00% | 1622.00% | 4409.00% | 5.77% | 0.10 | 2267.25% | 0.38% | 9.90% | 5.08% | 21.10 | 17.65 | 0.26 | 5.91 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| VRTX | Vertex Pharmaceuticals In… | $496.83 | 126.19B | -25% | -45% | -71% | -46% | 31.44 | 6.66 | 10.29 | 24.47 | — | 7.25 | 85.03% | 39.43% | 32.74% | 22.54% | 28.97% | 16.24% | 0.21 | 357.95 | 2.90 | 2.24 | -0.24 | -83654.00% | 957.00% | -50413.00% | 2.57% | 0.94 | 22.83% | 0.00% | 0.00% | 1.62% | 25.53 | 38.06 | 10.07 | 12.10 |
| ZTS | Zoetis Inc. | $131.10 | 57.77B | -7% | -40% | -99% | -53% | 21.39 | 17.17 | 6.04 | 15.82 | 212.77 | -131.77 | 70.49% | 38.00% | 28.23% | 65.99% | 28.56% | 18.00% | 2.85 | 14.80 | 3.03 | 1.75 | 1.76 | 1005.00% | 228.00% | -65.00% | 3.99% | 1.30 | 22.78% | 1.55% | 33.30% | 7.21% | 17.89 | 28.19 | 6.80 | 5.80 |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
- CEO
- Christopher S. Boerner
- Employees
- 34.1K
- Beta
- 0.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($31.14 ÷ $58.22) − 1 = -46.51% (DCF, example).